MYOS RENS Technology (MYOS) Receiving Positive News Coverage, Accern Reports

Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MYOS RENS Technology earned a coverage optimism score of 0.35 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.402885744962 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of MYOS RENS Technology (MYOS) remained flat at $$1.25 during midday trading on Monday. The stock had a trading volume of 17,451 shares, compared to its average volume of 128,342. MYOS RENS Technology has a 1-year low of $1.03 and a 1-year high of $3.28. The company has a market cap of $7.93, a PE ratio of -1.89 and a beta of 1.49.

How to Become a New Pot Stock Millionaire

Separately, ValuEngine raised MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3302653/myos-rens-technology-myos-receiving-positive-news-coverage-accern-reports.html.

About MYOS RENS Technology

MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Insider Buying and Selling by Quarter for MYOS RENS Technology (NASDAQ:MYOS)

Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WavesGo Price Hits $0.0298 on Major Exchanges
WavesGo Price Hits $0.0298 on Major Exchanges
DFSCoin Reaches Market Cap of $780,834.00
DFSCoin Reaches Market Cap of $780,834.00
Ceconomy  and GNC  Critical Survey
Ceconomy and GNC Critical Survey
Head to Head Contrast: CSG Systems International  and Mindbody
Head to Head Contrast: CSG Systems International and Mindbody
China Life Insurance  versus Its Rivals Head to Head Analysis
China Life Insurance versus Its Rivals Head to Head Analysis
Analysts Expect BeiGene  Will Post Earnings of -$1.96 Per Share
Analysts Expect BeiGene Will Post Earnings of -$1.96 Per Share


© 2006-2018 Ticker Report. Google+.